-The Times of India A six-member CBI and income tax team has begun examining over 5,800 tapes of recorded conversations of former corporate lobbyist Niira Radia with politicians, corporate honchos and others. The team, headed by a deputy inspector general-rank officer, started going through the tapes and its transcripts running into 49 volumes last week as per the directions of the Supreme Court in February, sources said. An apex court bench comprising...

-Live Mint CERC calls for a variable ‘compensatory tariff' to be offered to Adani Power till fuel situation stabilizes In an unprecedented move, India's apex power sector regulator offered a bailout package to Adani Power Ltd in a late Tuesday order to offset losses on account of the unexpected increase in the prices of imported coal and the unavailability of domestic coal for the company's 4,620 megawatts (MW) thermal power project at...

-The Indian Express Chennai: The fate of Sterlite Industries, and that of thousands of people of coastal Tuticorin, now depends on the south bench of the National Green Tribunal, which is hearing the company's petition against its closure ordered by the Tamil Nadu Pollution Control Board (TNPCB). The biggest copper smelting unit in the country, part of the Vedanta Group, moved the tribunal after the TNPCB ordered closure of the plant following...

-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...

-The Economic Times To ensure access to healthcare for all, India must harness innovation in discovering drugs, in developing therapeutics and in delivering affordable healthcare. It is in the light of these facts that one should evaluate the impact of the Indian Supreme Court's ruling in the case involving patent protection for Novartis AG's cancer drug, Glivec. Glivec was the first-of-its-kind cancer drug for leukaemia patients with patent protection in nearly 40...